Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRAT | O95237 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.72 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Neamine SCHEMBL29587258 | 1.00 | LRAT (1.00) | LRATLMNAKDM4EALOX15MEN1 | |
| Neamine SCHEMBL17677128 | 1.00 | LRAT (1.00) | LRATLMNAKDM4EALOX15MEN1 | |
| Neamine SCHEMBL12591591 | 1.00 | LRAT (1.00) | LRATLMNAKDM4EALOX15MEN1 | |
| Neamine SCHEMBL14445338 | 1.00 | LRAT (1.00) | LRATLMNAKDM4EALOX15MEN1 | |
| Neamine SCHEMBL12961240 | 1.00 | LRAT (1.00) | LRATLMNAKDM4EALOX15MEN1 | |
| Neamine SCHEMBL219578 | 1.00 | LRAT (1.00) | LRATLMNAKDM4EALOX15MEN1 | |
| Neamine SCHEMBL11590075 | 1.00 | LRAT (1.00) | LRATLMNAKDM4EALOX15MEN1 | |
| Neamine SCHEMBL6446250 | 0.99 | LRAT (0.97) | LRATLMNAKDM4EALOX15MEN1 | |
| Neamine SCHEMBL3669932 | 0.99 | LRAT (0.97) | LRATLMNAKDM4EALOX15MEN1 | |
| Neamine SCHEMBL1762107 | 0.99 | LRAT (0.97) | LRATLMNAKDM4EALOX15MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167148-A1 | MODULAR SYNTHESIS OF AMINOGLYCOSIDES | REVAGENIX, INC. | 2023-06-01 | — | — | US | disclosed |
| US-20220411456-A1 | MODULAR SYNTHESIS OF AMINOGLYCOSIDES | REVAGENIX, INC. (US) | 2022-12-29 | — | — | US | disclosed |
| EP-2235031-B1 | SYNTHESIS OF NOVEL NEAMINE DERIVATIVES AND USE THEREOF AS ANTIBACTERIAL AGENTS | Université Joseph Fourier (FR) | 2017-07-26 | — | — | EP | disclosed |
| US-20160282357-A1 | METHODS AND COMPOSITIONS RELATED TO NUCLEIC ACID BINDING ASSAYS | Nubad, LLC | 2016-09-29 | — | — | US | disclosed |
| US-9410186-B2 | Methods and compositions related to nucleic acid binding assays | NUBAD LLC (US) | 2016-08-09 | — | — | US | disclosed |
| US-9017943-B2 | Methods and compositions related to nucleic acid binding assays | NUBAD LLC (US) | 2015-04-28 | — | — | US | disclosed |
| US-20140330001-A1 | METHODS AND COMPOSITIONS RELATED TO NUCLEIC ACID BINDING ASSAYS | Nubad, LLC (US) | 2014-11-06 | — | — | US | disclosed |
| US-8729035-B2 | Synthesis of novel neamine derivatives and use thereof as antibacterial agents | UNIVERSITE JOSEPH FOURIER (FR) | 2014-05-20 | — | — | US | disclosed |
| US-8729035-B2 | Synthesis of novel neamine derivatives and use thereof as antibacterial agents | UNIVERSITE JOSEPH FOURIER (FR) | 2014-05-20 | — | — | US | disclosed |
| US-20140024137-A1 | METHODS AND COMPOSITIONS RELATED TO NUCLEIC ACID BINDING ASSAYS | NUBAD LLC | 2014-01-23 | — | — | US | disclosed |
| US-7626005-B2 | Inhibitors of aminoglycoside 6′-N-acetyltransferases, compositions and uses thereof | MCGILL UNIVERSITY (CA) | 2009-12-01 | — | — | US | disclosed |
| US-7626005-B2 | Inhibitors of aminoglycoside 6′-N-acetyltransferases, compositions and uses thereof | MCGILL UNIVERSITY (CA) | 2009-12-01 | — | — | US | disclosed |
| WO-2009095588-A2 | SYNTHESIS OF NOVEL NEAMINE DERIVATIVES AND USE THEREOF AS ANTIBACTERIAL AGENTS | UNIVERSITE JOSEPH FOURIER (FR) | 2009-08-06 | — | — | WO | disclosed |
| US-7514404-B2 | PNA-neamine conjugates and methods for producing and using the same | UNIVERSITY OF MEDICINE & DENTISTRY OF NEW JERSEY (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514404-B2 | PNA-neamine conjugates and methods for producing and using the same | UNIVERSITY OF MEDICINE & DENTISTRY OF NEW JERSEY (US) | 2009-04-07 | — | — | US | disclosed |
| US-20070225239-A1 | Pna-Neamine Conjugates and Methods for Producing and Using the Same | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-09-27 | — | — | US | disclosed |
| US-20070225239-A1 | Pna-Neamine Conjugates and Methods for Producing and Using the Same | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-09-27 | — | — | US | disclosed |
| US-7244712-B2 | Aminoglycoside antibiotics and methods of using same | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244712-B2 | Aminoglycoside antibiotics and methods of using same | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-07-17 | — | — | US | disclosed |
| WO-2004093821-A2 | TREATMENT OF ANTHRAX INFECTION USING INHIBITORS OF LETHAL FACTOR PROTEASE ACTIVITY | HAWAII BIOTECH, INC. (US) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225239-A1 | Pna-Neamine Conjugates and Methods for Producing and Using the Same | NCL, PNMT, RNMT | LRAT 739/4885LMNA 126/4885KDM4E 4632/4885 |
| US-20230167148-A1 | MODULAR SYNTHESIS OF AMINOGLYCOSIDES | MRPL21, COASY, AARS1 | LRAT 945/4885LMNA 2679/4885KDM4E 3762/4885 |
| US-20220411456-A1 | MODULAR SYNTHESIS OF AMINOGLYCOSIDES | MRPL21, COASY, AARS1 | LRAT 945/4885LMNA 2679/4885KDM4E 3762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.